ArcherDx to Develop CDx for Celgene's Lymphoma Drug Candidate

Nov 06, 2017

|

NEW YORK (Genomeweb) – ArcherDx announced on Monday an agreement to develop and commercialize a next generation sequencing-based companion diagnostic for Celgene's investigational drug CC-122 for diffuse large B cell lymphoma.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Scott Gottlieb Goes Back to His Old Job

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Where No CRISPR Has Gone Before

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Two Leave Emory

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

This Week in Science

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Featured White Papers

Evaluation of the Oncomine BRCA Research Assay for Variant Detection by Next-Generation Sequencing

Menu